Shattuck Labs, Inc.

NASDAQ:STTK

Biotechnology

Healthcare
$4.47 +2.33%

+$0.11 today

Market cap
$455.24M
Beta
1.09
P/E (TTM)
-10.9
EPS (TTM)
-$0.44
52W Low $0.71High $8.33

Volume 2.08M

Average 0.69M

STTK Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Shattuck Labs, Inc.NASDAQ: STTK

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $1M. Over 3 fiscal years it compounded at +15.3% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 6 analysts of $100K (-90.0%) for the fiscal year ending Dec 2026, a slowdown from the -82.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$1M-82.5% YoY
LTMMar 2026
$1M-78.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-82.5%-90.0%-7.5 pp
3-year CAGR+15.3%-41.5%-56.8 pp
5-year CAGR-8.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
1M USD
Year-over-year change
-82.5%
4-year CAGR
-57.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How STTK compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -78.3% is the 3rd highest of 5, against a peer median of -51.2%.
  • Over three fiscal years its annual growth of +15.3% compares with a peer median of +212.5%.
STTK Competitors
Revenue for STTK and competitors
Company Period LTM YoY 3-year CAGR
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$378.98M USD+51.3%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$227.18M USD-2.4%+0.0%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$11.88M USD—+424.9%
STTKShattuck Labs, Inc.LTM Mar 2026$1M USD-78.3%+15.3%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD——
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD——
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$0 USD——
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY-100.0%—
FTHFaeth Therapeutics, Inc.LTM Jun 2026-$4.85M USD——
Peer median (excluding STTK) —-51.2%+212.5%

Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.02M652K1.66M5.72M1M
Cost of Revenue1.38M82.2M4.04M4.89M0
Gross Profit28.64M(81.55M)(2.39M)827K1M
Gross Margin95.4%-12507.2%-143.9%14.5%100.0%
Research & Development56.56M82.9M74.31M67.21M35.27M
Selling, General & Admin18.72M19.68M19.3M19.08M17.24M
Operating Expenses73.91M21.78M89.57M81.39M52.51M
Depreciation & Amortization1.38M3.07M4.04M3.83M3.69M
EBITDA(43.59M)(98.87M)(83.26M)(71.58M)(45.12M)
EBITDA Margin-145.2%-15164.4%-5024.5%-1251.2%-4512.1%
Operating Income(45.27M)(103.33M)(91.96M)(80.57M)(51.51M)
Operating Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%
Interest Income625K1.59M4.67M5.17M2.7M
Interest Expense00000
Other Income / Expenses295K1.38M4.66M5.16M2.7M
Income Before Tax(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Pre-Tax Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
Income Tax Expense00000
Net Income(44.97M)(101.95M)(87.3M)(75.41M)(48.81M)
Net Margin-149.8%-15635.7%-5268.4%-1318.1%-4880.9%
EPS (Basic)(1.07)(2.41)(2.05)(1.49)(0.70)
EPS (Diluted)(1.07)(2.41)(2.05)(1.49)(0.70)
Weighted Avg Shares42.03M42.38M42.6M50.76M69.58M
Weighted Avg Shares (Diluted)42.03M42.38M42.6M50.76M69.58M

Shattuck Labs, Inc.

NASDAQ:STTK

Intrinsic Alpha fair value

Locked

Current Price

$4.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.